JUNO THERAPEUTICS Inc
44.6800
1.15%
44.6800
1.15%
17.5200 61.5900
52 weeks
52 weeks

Mkt Cap 4.74B

Shares Out 106.10M

new Chat
Send me real-time posts from this site at my email

Juno Therapeutics Announces Data Presentations at the American Association for Cancer Research Annual Meeting

SEATTLE--(BUSINESS WIRE)--

Juno Therapeutics, Inc. (JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced the Company, in partnership with its collaborators, will present clinical and pre-clinical data from multiple product candidates at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana from April 16-20.

There will be two presentations with clinical updates. On April 18th, Dr. Terry Fry will present the pre-clinical and clinical rationale as well as updated data from the ongoing Phase I trial of JCAR018, a chimeric antigen receptor (CAR) T cell product candidate targeting CD22, in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r ALL). On April 20th, Dr. Phil Greenberg will present the pre-clinical rationale as well as the first clinical data in patients with solid organ tumors for JTCR016, a T cell receptor (TCR) cell product candidate targeting Wilms tumor-1 (WT-1).

Dr. Hy Levitsky, Juno’s Executive Vice President, Research and Chief Scientific Officer, will discuss pre-clinical data that informed the rationale and design of the ongoing Phase 1 trial for JCAR024, a CAR T cell product candidate targeting ROR-1, in ROR-expressing tumors. Additionally, two Juno-sponsored posters will be presented and Juno’s investigational CAR T cell product candidates will be featured in three additional presentations.

Clinical and Pre-Clinical Updates

CD22 CAR Update and Novel Mechanisms of Leukemic Resistance

  • Presenter: Terry J. Fry, M.D., Investigator, Pediatric Oncology Branch and Head of Hematologic Malignancies Section, National Cancer Institute, National Institutes of Health
  • Date: Monday, April 18, 2016: 12:35 – 12:58 p.m. Eastern Time
  • Location: Room 243

Targeting Cancer with Engineered T Cells

  • Presenter: Phil Greenberg, M.D., Head of Program in Immunology at the Fred Hutchinson Cancer Research Center and Professor, Medicine/Oncology and Immunology, University of Washington
  • Date: Wednesday, April 20, 2016: 10:55 – 11:20 a.m. Eastern Time
  • Location: New Orleans Theater B

Pre-Clinical Updates

ROR1 Targeted by CAR T Cells

  • Presenter: Hy Levitsky, M.D., Juno’s Executive Vice President, Research and Chief Scientific Officer
  • Date: Tuesday, April 19, 2016: 1:05 – 1:30 p.m. Eastern Time
  • Location: New Orleans Theater C

Toxicity and Efficacy Probability Intervals Design for Phase I Dose-Finding in Oncology Trials

  • Authors: Daniel Li, Ph.D., et al., Juno Department of Clinical Statistics
  • Date: Sunday, April 17, 2016: 1:00 – 5:00 p.m. Eastern Time
  • Location: Section 20, Poster Board #29

Comprehensive TIL...


More
Cancel